Bayer and AskBio expand grand gene therapy ambitions with new Parkinson's program, top scientist
It only took 20 years, but Jude Samulski is finally turning AskBio into a gene therapy behemoth in the hills of North Carolina.
The now Bayer-owned biotech announced Thursday they were bringing over the clinical team from Brain Neurotherapy Bio, completing a buyout tipped in December and adding clinical programs in Parkinson’s and multiple system atrophy to an already large pipeline.
AskBio launched BrainNeuBio in 2018, a move consistent with Samulski’s long-running strategy of spinning out promising programs, which led to the Bamboo Therapeutics and Pfizer’s Duchenne Gene Therapy program, as well as a hemophilia program now owned by Takeda.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.